HIV vaccine vCP2438

Drug Profile

HIV vaccine vCP2438

Alternative Names: ALVAC-HIV-vCP2438; vCP2438

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator Sanofi Pasteur
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III HIV-1 infections

Most Recent Events

  • 01 Oct 2016 Phase-II/III clinical trials in HIV-1 infections (Prevention) in South Africa (IM) (NCT02968849)
  • 01 Jan 2015 Phase-I/II clinical trials in HIV-1 infections (Prevention) in South Africa (IM) (NCT02404311)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top